• About Us
    • Contact Us
    • Login
    • ObGFirst
  • COVID-19
  • Alerts
  • OB
  • 2T US Atlas
  • The Genome
  • GYN
    • GYN
    • Sexual Health
  • Primary Care
  • Your Practice
  • GrandRounds
  • My Bookshelf
  • Now@ObG
  • Media
About Us Contact Us Login ObGFirst
  • COVID-19
  • Alerts
  • OB
  • 2T US Atlas
  • The Genome
  • GYN
    • GYN
    • Sexual Health
  • Primary Care
  • Your Practice
  • GrandRounds
  • My Bookshelf
  • Now@ObG
  • Media
Grand Rounds

Oral Fluconazole Exposure in Pregnancy and Associated Risks for Adverse Events

image_pdfFavoriteLoadingFavorite

BACKGROUND AND PURPOSE:

  • Vaginal candidiasis is common in pregnancy (10%; 2-10 higher than general population)
  • High-dose fluconazole has been associated with significant birth defects
  • Bérard et al. (CMAJ, 2019) assessed the impact of fluconazole exposure during pregnancy on the occurrence of spontaneous abortions, major congenital malformations and stillbirths

METHODS:

  • Nested case-control studies
    • Secondary analysis of Quebec Pregnancy cohort
  • Women had been exposed to
    • Low (≤ 150 mg) fluconazole
    • High-dose (> 150 mg) fluconazole
    • No fluconazole exposure
  • For each case of spontaneous abortion or stillbirth, up to 5 controls were randomly selected and matched for
    • Spontaneous abortion: Gestational age at diagnosis
    • Stillbirth (index date): Year of the last menstrual period
  • All liveborn births acted as controls for cases of major congenital malformation

RESULTS:

  • Overall cohort of 441,949 pregnancies
    • For analysis of spontaneous abortions: 320,868 pregnancies included
    • Major congenital anomalies: 226,599 pregnancies included
    • Stillbirths: 7,832 pregnancies were included
  • Exposure
    • Low dose: 69.5% of women
    • High dose: 30.5% of women
  • Spontaneous abortion
    • Oral fluconazole exposure was associated with an increased risk of spontaneous abortion compared with no exposure
    • Low dose (n=345 exposed): Adjusted odds ratio (OR) 2.23 (95% CI, 1.96–2.54)
    • High dose (n-249 exposed) adjusted OR: OR 3.20 (95% CI, 2.73–3.75)
  • Major Malformations (overall)
    • No associated risk with first trimester exposure
  • Cardiac septal closure anomalies
    • Increaed risk with high dose exposure during the first trimester
    • Adjusted OR 1.81 (95% CI, 1.04–3.14)
  • Stillbirth: No associated risk

CONCLUSION:

  • Fluconazole exposure in pregnancy may increase risk of spontaneous abortion
  • Dose > 150 mg in first trimester may increase risk of cardiac septal closure anomalies
  • Professional bodies urge caution in prescribing fluconazole in pregnancy advise that other alternative antifungal agents be used to treat candidiasis in pregnancy (see ‘Learn More’ and ‘Related ObG Topics’ below)

Learn More – Primary Sources: 

Associations between low- and high-dose oral fluconazole and pregnancy outcomes: 3 nested case–control studies 

SOGC Statement on the Use of Fluconazole during Pregnancy 

Now You Can Get ObG Clinical Research Summaries Direct to Your Phone

Learn More »

image_pdfFavoriteLoadingFavorite
< Previous
All Grand Rounds Posts
Next >

Related ObG Topics:

FDA Reviews Fluconazole in Pregnancy
Is Oral Fluconazole Use in Pregnancy Linked to Stillbirths?
Desquamative Vaginitis—How to Recognize and Treat It

Sections

  • COVID-19
  • Alerts
  • OB
  • GYN
    • GYN
    • Sexual Health
  • 2T US Atlas
  • The Genome
  • Primary Care
  • Your Practice
  • Grand Rounds
  • My Bookshelf
  • Now@ObG
  • Media

Are you an
ObG Insider?

Get specially curated clinical summaries delivered to your inbox every week for free

  • Site Map/
  • © ObG Project/
  • Terms and Conditions/
  • Privacy/
  • Contact Us/
© ObG Project
SSL Certificate


  • Already an ObGFirst Member?
    Welcome back

    Log In

    Want to sign up?
    Get guideline notifications
    CME Included

    Sign Up

Download Your ObG App
HERE!

Sign In

Lost your password?

Sign Up for ObGFirst and Stay Ahead

  • - Professional guideline notifications
  • - Daily summary of a clinically relevant
    research paper
  • - Includes 1 hour of CME every month

ObGFirst Free Trial

Already a Member of ObGFirst®?

Please log in to ObGFirst to access the 2T US Atlas

Password Trouble?

Not an ObGFirst® Member Yet?

  • - Access 2T US Atlas
  • - Guideline notifications
  • - Daily research paper summaries
  • - And lots more!
ObGFirst Free Trial

Media - Internet

Computer System Requirements

OBG Project CME requires a modern web browser (Internet Explorer 10+, Mozilla Firefox, Apple Safari, Google Chrome, Microsoft Edge). Certain educational activities may require additional software to view multimedia, presentation, or printable versions of their content. These activities will be marked as such and will provide links to the required software. That software may be: Adobe Flash, Apple QuickTime, Adobe Acrobat, Microsoft PowerPoint, Windows Media Player, or Real Networks Real One Player.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information
presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Jointly provided by

NOT ENOUGH CME HOURS

It appears you don't have enough CME Hours to take this Post-Test. Feel free to buy additional CME hours or upgrade your current CME subscription plan

Subscribe

JOIN OBGFIRST AND GET CME/CE CREDITS

One of the benefits of an ObGFirst subscription is the ability to earn CME/CE credits from the ObG entries you read. Tap the button to learn more about ObGFirst

Learn More
Leaving ObG Website

You are now leaving the ObG website and on your way to PRIORITY at UCSF, an independent website. Therefore, we are not responsible for the content or availability of this site